Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia

NARecruitingINTERVENTIONAL
Enrollment

21,000

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
HCV Infection
Interventions
DRUG

Sofosbuvir/Daclatasvir

Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.

Trial Locations (4)

Unknown

NOT_YET_RECRUITING

Battambang Provincial Hospital, Battambang

RECRUITING

Kantha Bopha, Phnom Penh

RECRUITING

National Pediatric Hospital, Phnom Penh

RECRUITING

Jayavarman VII Hospital, Siem Reap

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV